Biodesix (NASDAQ:BDSX - Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $19.92 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
Biodesix Stock Performance
NASDAQ:BDSX traded down $0.02 on Thursday, hitting $0.81. The stock had a trading volume of 106,293 shares, compared to its average volume of 391,592. Biodesix has a 52-week low of $0.75 and a 52-week high of $2.04. The stock has a market cap of $118.28 million, a price-to-earnings ratio of -2.08 and a beta of 1.06. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The business's 50-day simple moving average is $1.16 and its two-hundred day simple moving average is $1.44.
Insider Buying and Selling at Biodesix
In related news, CEO Scott Hutton sold 83,660 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 128,702 shares of company stock valued at $118,406 over the last 90 days. 69.20% of the stock is currently owned by corporate insiders.
Biodesix Company Profile
(
Get Free Report)
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
Read More
Before you consider Biodesix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.
While Biodesix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
